Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 2491 • ACR Convergence 2023
Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort
Stefan Krämer¹, Thomas Rauen¹, Kristian Vogt¹, Teresa Anslinger¹, Martin Busch², Tobias Schmitt³, Raoul Bergner⁴, Sebastian Mosberger⁴ and Thomas Neumann⁵, ¹RWTH, University Hospital Aachen, Department of Nephrology and Rheumatology, Aachen, Germany, ²University Hospital Jena, Friedrich-Schiller University, Department of Internal Mediciine III, Jena, Germany, ³University Hospital Jena, Friedrich Schiller University, Department of Nephrology, Jena, Germany, ⁴Municipal Hospital Ludwigshafen, Department of Internal Medicine A, Nephrology and Rheumatology, Ludwigshafen, Germany, ⁵Cantonal Hospital St. Gallen, Department of Rheumatology, St. Gallen, Switzerland
Background/Purpose: In 2022, ACR and EULAR proposed new classification criteria for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) based on a numerical item scoring…
Abstract Number: 0683 • ACR Convergence 2023
Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Duvuru Geetha¹, Frank Cortazar², Annette Bruchfeld³, alexandre Karras⁴, Peter Merkel⁵ and David Jayne⁶, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³Karolinska Institutet, Stockholm, Sweden, ⁴HEGP - APHP, Paris, France, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the Phase 3 ADVOCATE trial comparing avacopan to a prednisone taper, 81% of patients with ANCA-associated vasculitis (AAV) had renal involvement based on…
Abstract Number: 1534 • ACR Convergence 2023
ANCA-associated Vasculitis Incidence in a Norther Spanish Health Region
Salma Al Fazazi¹, Fabricio Benavides², Alba Herrero-Morant³, Vanesa Calvo Río⁴, monica renuncio garcia², clara escagedo Cagigas², maria rodriguez Vidriales² and Ricardo Blanco⁵, ¹Hospital Universitario Puerta Del Mar, Cádiz, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ⁴Valdecilla Hospital, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Precise estimation of the…
Abstract Number: 2372 • ACR Convergence 2023
Soluble Triggering Receptor Expressed on Myeloid Cell-1 Reflects the Cross-sectional Activity of Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Jang Woo Ha¹, Jason Jungsik Song², Yong-Beom Park², Sung Soo Ahn² and Sang-Won Lee³, ¹Yonsei University College of Medicine, Seodaemun-gu, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, South Korea, ³Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: This study investigated whether the soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflects the cross-sectional activity of microscopic polyangiitis (MPA) and granulomatosis with…
Abstract Number: 2492 • ACR Convergence 2023
The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life
Rula Hajj-Ali¹, Chao Zhang², Renee Borchin³, Jenn Gordon⁴, David Cuthbertson³, Carol McAlear⁵, Christine Yeung⁵, David Badenoch⁶, Cristina Burroughs³ and Peter Merkel⁵, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³University of South Florida, Tampa, FL, ⁴Vasculitis Patient Powered Research Network (VPPRN), Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Vasculitis Patient Powered Research Network (VPPRN), Los Angeles, CA
Background/Purpose: Neurologic involvement (NI) is a common manifestation in patients with ANCA-associated vasculitis (AAV) and can lead to chronic pain and disability. This project assessed…
Abstract Number: 093 • 2023 Pediatric Rheumatology Symposium
Comparison Between Induction with Rituximab and Cyclophosphamide in Treatment of Childhood-Onset ANCA-Associated Vasculitis
Samuel Gagne¹, Kimberly Morishita², Else Bosman³, Vidya Sivaraman⁴, David Cabral⁵, For the PedVas Investigators⁶ and Brett Klamer⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²University of British Columbia, Vancouver, BC, Canada, ³UBC, Vancouver, BC, Canada, ⁴Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁵BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁶PedVas, ⁷Biostatistics Resource at Nationwide Children’s Hospital (BRANCH), Nationwide Children’s Hospital, Columbus, OH
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are a group vasculitides with significant morbidity and mortality requiring toxic therapy. Clinical trials in adults…
Abstract Number: L16 • ACR Convergence 2022
Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
Benjamin Terrier¹, Laura Richert², Grégory Pugnet³, Olivier Aumaitre⁴, Olivier Moranne⁵, Elisabeth Diot⁶, Alexandre Karras⁷, Fabrice Bonnet⁸, Claire De Moreuil⁹, Eric Hachulla¹⁰, Thomas Le Gallou¹¹, Céline Lebas¹⁰, Francois Maurier¹², Cédric Rafat⁷, Maxime Samson¹³, Jean-Francois Augusto¹⁴, Grégoire Couvrat-Devergne¹⁵, Cécile Janssen¹⁶, Thierry Martin¹⁷, Thomas Quemeneur¹⁸, Pierre-Louis Caron¹⁹, Cécile-Audrey Durel²⁰, Khalil El Karoui⁷, Aurélie Grados²¹, Mathieu Puyade²², Virginie Rieu⁴, Yurdagul Uzunhan²³, Jean-Francois Viallard⁸, Xavier Puéchal⁷, Loic Guillevin⁷, Noémie Huchet⁸, Hendy Abdoul⁷, Carine Bellera⁸, Frédéric Batteux⁷ and Odile Launay⁷, ¹Cochin Hospital, Paris, France, ²EUCLID, Bordeaux, France, ³CHU, Toulouse, France, ⁴CHU, Clermont-Ferrand, France, ⁵CHU, Nimes, France, ⁶CHU, Tours, France, ⁷CHU, Paris, France, ⁸CHU, Bordeaux, France, ⁹CHU, Brest, France, ¹⁰CHU, Lille, France, ¹¹CHU, Rennes, France, ¹²CH, Metz, France, ¹³CHU, Dijon, France, ¹⁴CHU, Angers, France, ¹⁵CH, La Roche sur Yon, France, ¹⁶CH, Annecy, France, ¹⁷CHU, Strasbourg, France, ¹⁸CH, Valenciennes, France, ¹⁹CHU, Grenoble, France, ²⁰CHU, Lyon, France, ²¹CH, Niot, France, ²²CHU, Poitiers, France, ²³CHU, Bobigny, France
Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…
Abstract Number: 0445 • ACR Convergence 2022
Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis
Ana Arevalo¹, Palak Shah², Harshvardhan Zala³, Faris Haddadin⁴, Monil Majmundar⁵ and Andrea Ramirez Gomez¹, ¹University of Chicago, Chicago, IL, ²Metropolitan Hospital Center, New York Medical College, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Several studies have reported that patients with ANCA-associated vasculitis (AAV) are at increased risk of cardiovascular complications from accelerated atherosclerosis with an excess cardiovascular…
Abstract Number: 0526 • ACR Convergence 2022
Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial
Lynn Fussner¹, Luis Felipe Flores-Suarez², Rodrigo Cartin-Ceba³, Ulrich Specks³, P. Gerard Cox⁴, David Jayne⁵, Peter Merkel⁶ and Michael Walsh⁴, ¹The Ohio State University, Columbus, OH, ²Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, ³Mayo Clinic, Rochester, MN, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
Abstract Number: 1082 • ACR Convergence 2022
Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
Pratyusha Banik¹, Marcia Friedman², Daniela Ghetie³, Dongseok Choi⁴ and Margaret Brophy¹, ¹Oregon Health & Science University, Portland, OR, ²Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, ³Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Lake Oswego, OR, ⁴OHSU-PSU School of Public Health, Portland, OR
Background/Purpose: While there is established data regarding the induction and maintenance treatment of systemic or organ threatening granulomatosis with polyangiitis (GPA), there is limited data…
Abstract Number: 1948 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Hyun Ho Lee¹, Lauren Blazek² and Eveline Wu³, ¹The University of North Carolina Chapel Hill, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, NC
Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…
Abstract Number: 0446 • ACR Convergence 2022
The Burden of Coronary Artery Calcification in ANCA-Associated Vasculitis
Anushri Parakh¹, Claire Cook¹, Xiaoqing Fu¹, sandeep hedgire¹, John Stone², Hyon Choi³, Michael Lu¹ and Zachary Wallace¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with an increased risk of cardiovascular (CV) disease, with MPO- AAV conferring a higher risk of CV events than…
Abstract Number: 0527 • ACR Convergence 2022
Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials
Florence Delestre¹, Pierre Charles², Loïc Guillevin³, Raphaël Porcher⁴ and Benjamin Terrier³, ¹cochin Hospital, Paris, France, ²Institut Mutualiste Montsouris, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Maintenance therapy after induction of remission has been shown to reduce relapse rate and mortality in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The three MAINRITSAN…
Abstract Number: 1083 • ACR Convergence 2022
Treatment of ANCA-associated Vasculitis with Extreme Impairment of Renal Function: A Case-Control Study Comparing an Intensive B Cell Depletion Regimen with the Standard of Care Using Oral Cyclophosphamide
Dario Roccatello¹, Savino Sciascia², Stefano Murgia¹, Giacomo Quattrocchio¹, Michela Ferro¹, Emanuele De Simone¹, Carla Naretto¹, Antonella Barreca¹, Daniela Rossi¹, Vittorio Modena¹ and Roberta Fenoglio¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitis associated with antineutrophil cytoplasm antibodies (AAV) in…
Abstract Number: PP03 • ACR Convergence 2022
To Err Is Human: The Need for Patients with Rheumatic and Musculoskeletal Diseases to Continuously Monitor Their Health Care Records
Ida Hakkarinen, Greenbelt, MD
Background/Purpose: In November 1999, the Institute of Medicine issued a press release announcing publication of To Err is Human: Building a Safer Health System (Kohn…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].